Plasma Fractionation Market Size & Share - Growth Analysis and Forecast 2026-2035

Plasma Fractionation Market - Regional Analysis

North America Market Insights

North America plasma fractionation market is anticipated to garner the highest share of 55.4% during the discussed timeframe. The region’s upliftment in this sector is largely propelled by the rising prevalence of immunodeficiency disorders, bleeding conditions, and chronic diseases that necessitate therapies derived from blood plasma. This expansion is also fueled by an aging population, increasing clinical adoption of immunoglobulins, and a well-established healthcare infrastructure with a high awareness of advanced biologic treatments. In October 2025, Grifols announced the U.S. launch of Yimmugo®, which is a 10% intravenous immunoglobulin (IVIg) developed by Biotest and approved by the FDA in 2024 for treating primary humoral immunodeficiency in patients aged 2 years and older.

High and growing clinical demand for plasma-derived therapies, especially immunoglobulins and coagulation factors are important factor driving the U.S. plasma fractionation market. The market benefits significantly from the country's status as the predominant hub for source plasma collection and is supported by an infrastructure of commercial donation centers and fractionation facilities.  In this context, ADMA Biologics in July 2023 received FDA approval for its ninth plasma collection center in Dallas, Georgia, to expand its capacity to collect human source plasma for the manufacture of plasma-derived therapies. This facility began collecting plasma in 2022 and uses advanced collection technology and automated registration, thus making it suitable for standard market growth.

The Canada market has a strong opportunity to grow in the upcoming years owing to a strategic shift toward long-term domestic security contracts. The country’s health authorities partner with global biopharmaceutical leaders to fractionate Canada-sourced plasma and guarantee a stable supply of finished therapies. This transition is also effectively supported by ongoing provincial initiatives to expand local plasma collection networks and reduce historical dependencies on imports. In addition, a rigorous regulatory environment overseen by Health Canada ensures high safety standards, whereas public funding models facilitate equitable patient access to these essential biologic medications, thus contributing to the market’s expansion.

APAC Market Insights

The Asia Pacific market is expanding at a notable rate, which is fueled by a massive patient population, rising awareness of rare genetic disorders, and increasing healthcare expenditures across emerging economies. Market growth is also driven by government initiatives that aim to reduce dependency on imported blood products by establishing domestic fractionation facilities and encouraging local plasma donation. In July 2026, Takeda and the government of Indonesia launched a multi-year collaboration to strengthen Indonesia’s plasma ecosystem, expand access to plasma-derived medicinal products, and enhance national healthcare resilience. Takeda will initially invest up to USD 30 million over a span of two years to pilot plasma donation centers, thus positively benefiting the market’s expansion.

The existence of stringent government policies which are aimed at achieving national self-sufficiency in blood products is powering the China plasma fractionation market. The rapid consolidation among state-backed and leading domestic biopharmaceutical companies, along with the strict regulation and expansion of local plasmapheresis stations, is positioning the market for extensive growth. Based on the government data published in June 2024, China’s National Medical Products Administration introduced a three-year action plan in order to accelerate digital and intelligent transformation across blood product manufacturing, to strengthen quality, safety, and regulatory oversight. This plan covers digital management of plasma receipt, blood product production and testing, as well as information-system compliance and security, thus contributing to market expansion.

The Japan plasma fractionation market is growing exponentially owing to the presence of an aging population and an increasing clinical requirement for plasma-derived therapies to treat disorders. The country’s market operates under a strict government-led philosophy of self-sufficiency, which prioritizes the utilization of domestic blood donations for the manufacturing of essential therapeutics such as immunoglobulins and albumin. Based on the government data published in November 2024, Japan’s Pharmaceutical Affairs Council reviewed the FY2025 blood donation and supply-demand plans, and it targets 2,240,000 liters of donated blood to support transfusion needs and domestic plasma-derived product manufacturing. The meeting also underscored growing demand for human immunoglobulin and the need to strengthen domestic fractionation capacity, and it is using imports to maintain short-term supply stability.

Europe Market Insights

The Europe market is projected to expand at a considerable rate as it possesses a mix of public, non-profit, and private plasma collection systems. Several countries in this region are moving toward legislative frameworks that support co-existence models to increase plasma collection volumes. Market growth is further propelled by advanced technological integration in manufacturing facilities and high clinical utilization guidelines for immunoglobulins. In June 2026, Grifols began construction of a new plasma-derived medicines manufacturing facility in Lliçà de Vall, Barcelona, with an initial investment of USD 184.3 million. This facility will increase Grifols’ Europe plasma fractionation capacity by three million liters annually, thus strengthening the region’s supply of immunoglobulins and other plasma-derived therapies.

The continuous investments from leading biopharmaceutical companies in expanding domestic manufacturing capacities and implementing viral safety and purification technologies are responsibly boosting the market in Germany. A highly organized healthcare infrastructure, efficient distribution networks, and robust reimbursement policies under the statutory health insurance system drive consistent growth of the country’s market. In this context, CSL in March 2023 opened a new USD 470 million plasma fractionation facility in Marburg, Germany, after five years of construction, thereby expanding its capacity to convert donated human plasma into essential medicines. This new CSL Behring facility uses advanced technology, automation, and optimized processes to quadruple the site’s existing plasma fractionation capacity.

The UK plasma fractionation market is growing at a rapid pace owing to an increasing clinical need for immunoglobulins and specific coagulation factors in order to treat primary immunodeficiencies and rare neurological conditions. Besides, this expansion is also supported by long-term strategic partnerships between the UK government and global biopharmaceutical leaders to fractionate UK-sourced plasma into finished therapies. Based on government data, which was published in August 2023, NHS England awarded a total of USD 814 million contract to Octapharma AG for the domestic fractionation of UK plasma and the supply of plasma-derived products, including albumin and immunoglobulins. In addition, this five-year supply contract runs from January 2025 through December 2029, supporting the NHS’s access to essential plasma-derived medicines from a UK-focused supply arrangement.